CLAIM CARD
The curated corpus is dominated by observational cohort designs; no large, long-term randomized controlled trial testing whether modulating epigenetic clocks extends human lifespan or reduces hard clinical endpoints such as incident dementia or cardiovascular death was represented. Consequently, the headline conclusion that accelerated epigenetic aging predicts adverse outcomes cannot be interpreted as causal, and the specific question of whether therapeutic epigenetic age reversal improves survival remains unanswered by this evidence base.
Evidence grade: exploratory
Contradiction status: none
Publication: 9e9f3163-3f3b-4c1f-9790-a8b1400b8696
Provenance: Derivation Web chain
Citation Support
source_1Bozack 2023source_2McGee 2024source_3Marinello 2025source_4Petersen 2021source_5Arpawong 2023